The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Alpha-gal syndrome (AGS) is a severe tick-vectored food allergy caused by sensitivity to the galactose-alpha-1,3-galactose ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Tiffany Renee Thomas is an experienced employment law attorney and HR professional whose career serves as an example of both ...

The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...

Q4 2024 Earnings Call Transcript March 10, 2025 Lineage Cell Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...